{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:46:33Z","timestamp":1782733593360,"version":"3.54.5"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00115-026-01984-1","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:13:45Z","timestamp":1781003625000},"page":"411-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dextromethorphan\/Bupropion zur Behandlung von Agitation bei Alzheimer-Demenz","Dextromethorphan-bupropion for the treatment of agitation in Alzheimer\u02bcs disease"],"prefix":"10.1007","volume":"97","author":[{"given":"Michael","family":"Paulzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"1984_CR1","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.2015.10214","volume":"314","author":"JL Cummings","year":"2015","unstructured":"Cummings\u00a0JL, Lyketsos\u00a0CG, Peskind\u00a0ER et\u00a0al (2015) Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. Jama 314:1242\u20131254","journal-title":"Jama"},{"key":"1984_CR2","unstructured":"FDA (2026) Prescribing Information Auvelity. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215430s009s018lbl.pdf. Zugegriffen: 13. Mai 2026"},{"key":"1984_CR3","doi-asserted-by":"crossref","unstructured":"Iosifescu DV, Jones A, O\u2019gorman C et\u00a0al. (2022) Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A\u00a0Phase\u00a03 Randomized Clinical Trial (GEMINI). J\u00a0Clin Psychiatry\u00a083","DOI":"10.4088\/JCP.21m14345"},{"key":"1984_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00115-025-01799-6","volume":"96","author":"M Paulzen","year":"2025","unstructured":"Paulzen\u00a0M (2025) Metamizole \/ dipyrone in psychiatry - What about the pharmacokinetics? Nervenarzt 96:197\u2013202","journal-title":"Nervenarzt"},{"key":"1984_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1017\/S1092852919001470","volume":"24","author":"SM Stahl","year":"2019","unstructured":"Stahl\u00a0SM (2019) Dextromethorphan\/Bupropion: A\u00a0Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. CNS Spectrums 24:461\u2013466","journal-title":"CNS Spectrums"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-01984-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:19:12Z","timestamp":1782731952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-01984-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-01984-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Paulzen erhielt in den letzten zwei Jahren Vortrags- und Beraterhonorare von folgenden pharmazeutischen Unternehmen: Lundbeck, Johnson&Johnson, Otsuka, Rovi, Recordati, Idorsia und Teva. Er ist Herausgeber von PSIAC, einem internetbasierten Arzneimittelinteraktionsprogramm f\u00fcr Psychopharmakotherapie (\n                      \n                      ). Bez\u00fcglich der Erstellung des Beitrags bestanden keine Interessenkonflikte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}